PHEBA PAPPACHAN: Open Payments
NPI 1053757179 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$203 in 6 payments from 6 companies in 2025. Trend: 2023 $102 · 2024 $226 · 2025 $203
Food & beverage: $203
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 1 | $84 |
| Lundbeck LLC | 1 | $31 |
| ABBVIE INC. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $17 |
Products named: ARISTADA, REXULTI, VRAYLAR, FANAPT, ERZOFRI EXTENDED-RELEASE, QUTENZA.
Industry payments across TX — which companies pay providers there.
